Krishna Gunturu, Medical Oncologist, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    Astra Zeneca
    Topic:
    NSCLC
    Date added:
    06/06/2024
    Date updated:
    06/06/2024
    Relationship end date:
    12/07/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consulting Fee
    Ineligible company:
    BMS
    Topic:
    Lung cancer
    Date added:
    06/06/2024
    Date updated:
    06/06/2024
    Relationship end date:
    12/06/2023
Return to Sept. 27-28, 2024 - Symposium for Evolving Therapies and Drug Development in Oncology